

Active substances set

Search phrase: inotuzumab ozogamicin

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Acute lymphoid leukemia

Inotuzumab ozogamicin

Inotuzumab Ozogamicin is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO